Travere Therapeutics (TVTX) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $83.0 million.
- Travere Therapeutics' Receivables - Net rose 22936.51% to $83.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.0 million, marking a year-over-year increase of 22936.51%. This contributed to the annual value of $27.1 million for FY2024, which is 2790.57% up from last year.
- Per Travere Therapeutics' latest filing, its Receivables - Net stood at $83.0 million for Q3 2025, which was up 22936.51% from $38.7 million recorded in Q2 2025.
- Over the past 5 years, Travere Therapeutics' Receivables - Net peaked at $83.0 million during Q3 2025, and registered a low of $11.9 million during Q2 2021.
- In the last 5 years, Travere Therapeutics' Receivables - Net had a median value of $20.4 million in 2023 and averaged $23.6 million.
- In the last 5 years, Travere Therapeutics' Receivables - Net plummeted by 2762.43% in 2021 and then surged by 22936.51% in 2025.
- Over the past 5 years, Travere Therapeutics' Receivables - Net (Quarter) stood at $15.9 million in 2021, then rose by 4.6% to $16.6 million in 2022, then rose by 27.23% to $21.2 million in 2023, then rose by 28.03% to $27.1 million in 2024, then surged by 206.09% to $83.0 million in 2025.
- Its Receivables - Net stands at $83.0 million for Q3 2025, versus $38.7 million for Q2 2025 and $34.4 million for Q1 2025.